What strategies can reduce development time and accelerate
access to next-generation monoclonal antibodies (mAbs) in the
evolving SARS-CoV-2 variant landscape?
Credit available for this activity expires: 1/26/25
Earn Credit / Learning Objectives & Disclosures: